Added to YB: 2026-09-11
Pitch date: 2026-09-10
VRTX [bullish]
Vertex Pharmaceuticals Incorporated
Author Info
No bio for this author
Company Info
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Market Cap
$132.1B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
22.32
P/E
30.33
EV/Sales
9.57
Sector
Biotechnology
Category
growth
Vertex in Transition: Reading Between the Lines of a Solid Quarter
VRTX (earnings): Vertex delivered a strong Q2, with revenue up 12.4% to $3.33B and cystic-fibrosis sales up 10.6%, but that franchise still generates roughly 96% of product revenue. The investment thesis remains attractive but conditional on four simultaneous bets: ALYFTREK expanding beyond TRIKAFTA substitution, CASGEVY and JOURNAVX converting adoption into revenue, povetacicept launching successfully, and the nearly $9B net Crinetics acquisition integrating without surprises.
Read full article (8 min)